Morise M, Kato T, Matsumoto S, Inoue T, et al. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer Sci 2024;115:1296-1305.
PMID: 38402853